Michael Shulman
Michael Shulman is the Editor of ChangeWave Biotech Investor, a newsletter advisory service that follows life sciences and biotech stocks. He also served as Managing Director of Research for ChangeWave Research for four years, where he produced technology and healthcare research for financial institutions.
Michael joined ChangeWave after spending 20 years in various high-tech industries. He began his career doing in-depth company and market analysis for a variety of companies, building databases and simulation models to estimate the success of various technologies across a wide range of market segments. He moved "inside" the high-tech community as a manager at high-tech companies including AT&T.
Michael was an early private investor in several Internet start-ups, notably XOOM.com (which went public in 1998 and was bought by NBC in 1999) and brings a unique perspective to the ChangeWave research effort, as a combination of technologist, investor and financial analyst.
He has been published in a variety of trade and general business publications, including the "Los Angeles Times," is a regular panel member on the FOX Business Channel and has appeared frequently on CNBC's "Squawk Box.”
Prior to taking on his current role as Editor of the ChangeWave Biotech Investor, he was Editor of ChangeWave Hedge Fund Investing and ChangeWave Insight, products designed for the institutional investor. He is also the editor of ChangeWave Shorts, a leading service for individual short side investors based on fundamental research.
Michael Shulman's Latest Articles
- The Bi-Polar Biotech Market Will Continue
-
Barrier's Turnaround Jump-Starts Revenue
on May 29, 2008 about BTRX
-
What Gives With Avant Immunotherapeutics?
on Apr 23, 2008 about AVAN
- Antigenics, Dendreon and Cell Genesys Find Hope in Overseas Treatment Approvals
- Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys?
-
Genentech's Avastin: An Undeserving Target for Politicians and the Media
on Mar 26, 2008 about DNA
-
Amgen: Valued on Profits, Not Growth
on Mar 20, 2008 about AMGN
-
Cepheid Takes Hit on False MRSA Testing Claim
on Mar 12, 2008 about CPHD
-
Prana Biotechnology's Alzheimer's Drug Could Challenge the FDA
on Feb 26, 2008 about PRAN
-
YM Biosciences' Trials Are Worth Watching
on Feb 21, 2008 about YMI
-
BioCryst Management Needs to Earn Investors' Trust
on Feb 05, 2008 about BCRX
- Alkermes, Lilly, Mannkind: Inhaled Insulin Just Got Interesting
-
Dendreon Suffers from Immature Management
on Jan 13, 2008 about DNDN
- Amgen: Boxed In
-
Cepheid: Is the MRSA Infection an Investment Opportunity?
on Jan 02, 2008 about CPHD
-
Is it Time to Run Away from Merck?
on Dec 25, 2007 about MRK
-
Questcor: The Non Orphan, Orphan Drug Company
on Dec 11, 2007 about QSC
-
4 Reasons Amgen Looks Anemic
on Dec 04, 2007 about AMGN
-
Elan: New Multiple Sclerosis Drug Sales Will Be Key
on Dec 03, 2007 about ELN
-
Is it Time to Buy Biogen-Idec?
on Nov 30, 2007 about BIIB
-
RNA Interference Stocks: Invest At Your Own Risk
on Jul 16, 2007 about ALNY
- Three 'Busted' Biotech IPOs: Amicus, Jazz, Sirtris
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Most Popular Feeds
-
ETFs
-
US Market
-
Long Ideas
-
Alt. Energy
- Full list of feeds »
Trading Center
Hedge Fund Jobs
Job Seekers:
- Search jobs by category
- Get job alerts by email or live feed
- Apply online
Employers
- See all recruitment options
- Get applications online or by email
- About Seeking Alpha
- About Us
- Contact Us
- What's New
- Readers Feedback
- Contributors
- Contribute an Article
- Feature Your Book
- Our Contributors
- Anonymous Contributions
- Dispute an Article?
- Tools & Widgets
- Stock Market Toolbar
- Stock Search Add-on
- Power Search
- Email Alerts
- Live Feeds (RSS)
- Legal
- Terms of Use
- Privacy
- Copyright
- Advertise
Want to talk to our community?
Got something interesting to say?
- Advertise with Us

Latest Commentson Michael Shulman's Articles